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Abstract
Background A history of illicit injecting drug use makes
indication of total hip arthroplasty (THA) in patients with
end stage hip osteoarthritis difficult, as the risk of infection
with colonized strains is multiplied if the patient continues
to inject or inhale illicit drugs.
Methods A retrospective survivorship analysis of a con-
secutive series of 27 THA in patients with a history of
illicit drug use was performed. Follow-up evaluation con-
sisted of (1) a WOMAC score, (2) a standardized interview
including queries on drug habits and eventual additional
medico-surgical treatments of the affected hip, (3) a clin-
ical examination in order to complete a Harris Hip Score,
(4) radiological examination and (5) blood tests (blood
sedimentation rates and C-reactive protein). Defined end-
points were death, implant revised or awaiting revision for
deep infection or any other reason and lost to follow-up or
follow-up after at least 2 years.
Results Overall, 5- and 10-year implant survival rates
with failure for any reason were 61 % (CI: 41;81) and
52.3 % (CI: 29;76) and for septic reasons 70.6 % (CI:
52;89) and 60.5 % (CI: 36;85), respectively. Even if at the
time of THA all patients and respective health care pro-
fessionals confirmed abstinence of illicit injecting drug use,
five patients reported occasional use. Declared abstinence
of less than 1 year before THA was associated with higher
recurrence rates (p = 0.001) and both with higher septic
failure rates (p = 0.023, p = 0.061). Positive serology for
human deficiency virus did not increase implant failure
rates.
Conclusion We use this unacceptable high failure rate as
evidence when counseling patients and their health care
professionals about the appropriate treatment of osteoarthritis
in patients with a history of illicit drug use. Furthermore, we
support the request of hair analysis for drugs documenting
abstinence of at least 1 year before indicating THA.
Keywords Hip arthroplasty  Survivorship analysis 
Illicit drug abuse
Introduction
Illicit injecting drug use has a long history, but it was in the
early 1980s, with the rapid growth of intravenous heroine
use and the spread of the human immunodeficiency virus
(HIV), that this behavior gained prominence as a core
element of Europe’s and the world’s drug problem. Today
the estimated prevalence of injecting drug users is about
2.5 per 1,000 individuals aged 15–64 years, which corre-
sponds to a total number of up to one million active
injecting drug users in the 27 Member States of the
European Union [1].
In developed countries, illicit injecting drug users have an
increased risk of premature death from drug overdose, vio-
lence, suicide, alcohol-related causes and AIDS. Further-
more, the prevalence of infection with hepatitis B, C and
human immunodeficiency virus is estimated to be greater
than 60 % [2] and 12 % [3], respectively. In HIV patients
undergoing antiviral therapy, the risk of osteonecrosis of the
femoral head (ONFH) is increased [4–6], with a prevalence
of approximately 0.74 % [4]. ONFH, together with inflam-
matory arthropathies due to repetitive bacteremia [7] and
posttraumatic conditions are the main reasons for secondary
hip osteoarthritis in illicit injecting drug users.
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The treatment strategy for illicit injecting drug users pri-
marily aims to reduce drug injection-related harm and
gradual reintegration of patients into normal working life and
assimilation into the social community. Secondary hip
osteoarthritis may sometimes compromise return to work
and thus social reintegration. In such conditions orthopedic
surgeons may be approached for adequate treatment of hip
osteoarthritis. When total hip arthroplasty (THA) is antici-
pated, the risk of septic complications is a major concern,
since the risk to cause and spread infection with colonized
strains is known to be multiplied by injection or inhalation of
drugs [8, 9]. On the other hand, alternatives such as hip
arthrodesis or resection arthroplasty may hardly be perceived
to give the highest attainable standard of care by patients and
their supporting health care professionals, especially if
promising efforts to stop illicit drug use have been made.
During the last decade it has been the practice of our
institution to accept patients with a history of illicit
injecting drug use for THA if they were in medical and
social care by professionals specialized in drug-related
problems and if abstinence from illicit drug use was
declared by patients and confirmed by their respective
healthcare professionals. It has been our impression that the
septic complication rates were higher than expected from a
normal population. Because of absence of any data on this
issue, a retrospective review of all patients with a history of
illicit drug use receiving THA in our department during the
last decade was undertaken.
Materials and methods
Our prospectively collected database on THA was retro-
spectively analyzed for patients with a history of illicit
injecting drug use undergoing THA between January 1999
and December 2009. From 2,625 primary THA performed
during this time period, a consecutive series of 24 patients
(27 THA), 17 male and 7 female, with an average of
43 years (range 28–55) was identified.
The study was approved by our institutional Human
Subject Review Board. Written consent was obtained from
all patients willing to attend a follow up visit. For those
denying, based on a general permit issued by the respon-
sible state agency, our institutional review board allows
retrospective analysis of patient data relating to standard
diagnostic or therapeutic procedures without individual
informed consent. There was no external funding for the
purpose of this study.
Treatment protocol
Before considering patients for THA, abstinence from
illicit injecting drug use had to be declared by patients and
confirmed by respective health care professionals and, in
case of positive serology for hepatitis C virus (HCV) and/
or HIV, patients had to be followed by a healthcare insti-
tution specialized in infectious disease. Additionally, blood
sedimentation rates (BSR) less than 35 mm/h and C-reac-
tive protein (CRP) levels less than 10 mg/L on preopera-
tive blood screenings were mandatory.
Surgeries were performed under a laminar air flow
system. Depending on the time period and underlying
pathology, either a mini-incision direct anterior approach
in the supine position (10 THA), or a transgluteal (14 THA)
or transtrochanteric (3 THA) approach in the lateral posi-
tion was used. Three doses of cefuroxime 1.5 g in an 8-h
interval starting 30 min before incision and enoxaparin
natrium on a daily dose for 6 weeks were given to all
patients. Depending on the time period, non-cemented (14
THA) or hybrid (non-cemented cup and cemented stem)
(13 THA) implants were used. One closed suction drain
lying under the fascia was used and removed after 48 h in
all cases.
Follow-up evaluation
All patients were invited by mail and asked for informed
consent to participate in our review. Follow-up evaluation
consisted of (1) a WOMAC score, (2) a standardized
interview including queries on drug habits and eventual
additional medico-surgical treatments of the affected hip,
(3) physical examination looking for clinical signs of
infection (open sinus, swelling, tenderness, warmth) in the
hip region and in order to complete a Harris Hip Score
(HHS), (4) radiological examination including an antero-
posterior and cross-table lateral view, which were compared
to the first postoperative X-rays and screened for radiolu-
cent lines [10, 11], periosteal new bone formation and
endosteal scalloping and (5) blood tests (BSR and CRP).
For patients not responding to our mail, our standardized
interview was conducted by phone. For all patients a chart
review recording all perioperative and postoperative com-
plications, and in patients lost, an analysis of the latest
available X-rays was performed. Defined endpoints were
death, implant revised or awaiting revision for septic or any
reason, lost to follow-up or follow-up after at least 2 years.
Septic failure was diagnosed if an open sinus, an abscess
formation, frank pus during surgery or positive intraoper-
ative culture from a subsequent surgical intervention were
recognized. Additionally, deep sepsis was suspected if at
least three of the following criteria were present: (1) ery-
thematous, swollen, fluctuating and tender surgical site, (2)
fever, chills or sweating, (3) old closed sinus, (4) elevated
BSR [35 mm/h and CRP [10 mg/L in the absence of
recent surgery, neoplasia, remote infection or other
inflammatory conditions, (5) periosteal new bone
1038 Arch Orthop Trauma Surg (2012) 132:1037–1044
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formation with or without endosteal scalloping or early
rapidly progressive radiolucent lines and (6) positive joint
aspiration.
Statistical analysis
Kaplan–Meier survivorship curves were compiled with
implant failure for septic and for any reason as endpoints,
respectively. For comparisons of categorical data between
groups a two sided Fisher Exact Probability Test was used.
All statistical analyses were performed using SPSS 17.0 for
Windows. The significance level was set at p \ 0.05.
Results
Indications for THA are summarized in Table 1. Seven
patients had previous surgery on the affected hip a mean of
6.6 years (range 0.3–31; SD 12.1) before the index THA.
Among these were two patients who had resection arthro-
plasty because of septic arthritis before. The course of all
patients is summarized in Table 2.
Six patients (8 THA’s) were lost to follow-up
or deceased
Two of them (3 THA’s) left for a foreign country and could
not be traced. One, left after septic implant revision
(Escherichia coli) 2 months after the index procedure, was
included in survivorship analysis. The other four patients (5
THA’s) died after a mean postoperative time of 24 months
(range 6–73, SD 33) unrelated to the surgery. Three had an
uneventful postoperative course. And one had a septic
revision 5 weeks after the index procedure (coagulase
negative Staphylococcus).
Four patients with telephone interview and chart review
Four refused a follow-up visit but telephone interview and
chart review revealed an uneventful course in two (24 and
98 months after THA) and septic revision in two, 24
(Staphylococcus aureus) and 69 months (coagulase nega-
tive Staphylococcus) after the index procedure.
Fourteen patients available for follow-up visit
After an average time of 69 (range 24–123; SD
38) months, nine patients (9 THA’s) had an uneventful
course, without any clinical signs of infection and perfect
radiological appearance of the THA. CRP levels and ESR
were normal in seven of them. Two had elevated values for
CRP (25 and 19) and BSR (38 and 29), one after a recent
pneumonia, and the other without detectable reason. There
overall mean HHS and WOMAC were 91 (range 71–100)
and 0.8 (range 0–2), respectively.
Two patients sustained a traumatic periprosthetic frac-
ture. One Vancouver type B2 fracture was recognized
11 months after the index procedure when loosening of the
implant together with a non-union was observed. Intraop-
erative tissue specimens sent for microbiological exami-
nation were negative. The other (Vancouver type B2)
fracture was due to a road traffic accident 6 months after
index procedure. This was treated with a long revision stem
in a foreign country; however this was complicated with a
postoperative deep infection (Staphylococcus aureus).
Both showed normal values for CRP and ESR at follow-up
examination. HHS (99 and 100 points) and WOMAC
scores (0 and 0 points) were excellent.
One patient was revised due to periprosthetic infection
(coagulase negative Staphylococci) 1 month after index
procedure. Treatment consisted of a one-stage implant
revision and ciprofloxacin and rifampicin for 3 months. At
follow-up, 27 months after the index procedure, no local
signs of infections were encountered and X-rays were
excellent. CRP measured 16 and ESR 25 mm/h. HHS was
89 and the WOMAC 0 points.
One patient with bilateral THA showed 30 months after
index surgery elevated CRP (26) and BSR (52) levels as
well as implant loosening with gross metaphyseal and
acetabular osteolysis on both sides (Fig. 1), but denied
further investigation such as hip aspiration for bacterio-
logical tests. However, due to clinical and radiological
findings, both hips were considered as septic failures.
One patient underwent surgical implant revision due to
deep infection with a total of three two-stage exchanges
because of recurrent infections, first with S. aureus 6 months
after the index procedure, second with Streptococcus mitis
and third with Streptococcus sanguis and Candida albicans.
A resection arthroplasty was finally performed.
Overall, from 25 THA (in 23 patients) followed until
implant failure, death or for a minimum of 24 months, 8 were
revised and 2 are awaiting revision. As a cause of failure,
deep sepsis was detected in 8 cases. Five- and 10-year
implant survival rates with failure for any reason were 61 %
(CI: 41;81) and 52.3 % (CI: 29;76) and for septic reasons
70.6 % (CI: 52;89) and 60.5 % (CI: 36;85), respectively.
Figure 2 shows Kaplan–Meier survivorship analysis.
Table 1 Indications for THA
Primary OA 7
Secondary OA
ONFH 10
Postinfectious OA 2
Posttraumatic OA 6
Childhood’s disease 2
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According to our chart review, abstinence from illicit
injection drug use at time of the index surgery was declared
to be greater than 10 years in six, greater than 1 year in ten
and less than 1 year in eight patients. Fourteen participated
in a medically controlled heroine prescription program.
The others were abstinent from illicit drug use without
substitution. In 5 of 24 patients, recurrence of illicit
injecting drug use was recorded either from the question-
naire or from the charts. All recurrences occurred in
patients having stopped illicit drug use for less than 1 year
before the index surgery (p = 0.001) and four of them
participated in a medically controlled heroine prescription
program (p = 0.36).
Four septic failures out of 5 THA’s occurred in patients
admitting illicit drug use recurrence and 3 septic failures
out of 20 THA’s in patients not admitting illicit drug use
recurrence (p = 0.023). Five septic failures out of 8 THA’s
occurred in patients having stopped illicit drug use for less
than 1 year and 3 out of 14 THA’s in patients having
stopped illicit drug use for more than 1 year (p = 0.061).
Fig. 1 X-ray of a 44-year-old man with bilateral osteonecrosis of the
femoral head (a). A minimal invasive total hip arthroplasty was
performed first on the right (b) and 6 weeks later on the left side (c).
Postoperative X-rays showed a non-symptomatic avulsion fracture of
the greater trochanter on the right side, which was treated
conservatively. 30 months after index procedure the patient presented
elevated BSR and CRP levels as well as implant loosening, cup
dislocation and gross metaphyseal and acetabular osteolysis on both
sides (d). Although he denied joint aspiration and any kind of surgical
treatment, both hips were considered as septic failures
months
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Implant Survivorship Analysis
year n survival 95% CI
2 16 75.3% 58-92%
5 7 70.6% 52-89%
10 1 60.5% 36-85%
year n survival 95% CI
2 15 71.3% 53-89%
5 7 61.0% 41-81%
10 1 52.3% 29-76%
Fig. 2 Kaplan–Meier survivorship analysis with implant failure for
septic and for any reasons as endpoints
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Seven patients had positive serology for HIV, 16 for
HCV and 6 for both, all under a medically supervised
treatment protocol. None of the THA’s implanted in HIV-
positive patients were revised because of deep sepsis.
At time of index surgery 19 patients were smoking at
least ten cigarettes a day, 6 admitted to daily smoking and
further 8 occasionally abused alcohol.
Discussion
In this retrospective analysis the 10-year cumulative septic
implant revision rate of THA in patients with a history of
illicit injecting drug use was as high as 39.5 % (CI: 15;64)
and verified our concerns about an unacceptable high risk
of septic complications in this population.
During the last decade, 1 % of primary THA’s were
performed in patients with a history of illicit injecting drug
abuse in our institution. This is more than would be
expected when considering the approximately 30,000 illicit
injecting drug users in our country, representing about
0.4 % of our population. The urban location of our
department and our practice to accept patients with a his-
tory of illicit injecting drug use for THA may explain this
higher than expected rate.
With a mean age of 43 years, our patient population
represents a relatively young group undergoing THA. This
is most likely attributable to the etiology of osteoarthritis
being femoral head osteonecrosis and septic arthritis in
nearly half of the cases, which both are considered typical
hip-specific complications of illicit injecting drug abuse
and HIV.
Despite this young patient collective, four of 23 patients
died during the follow-up period. Injecting drug use related
deaths primarily occur among young adults and accounts
for a large number of life years lost in developed societies.
In Scotland and Spain for example, injecting drug related
deaths accounts for 25–33 % of deaths of young adult
males.
The high percentage of patients with positive serology
for HIV (29 %) and HCV (54 %) is a known association in
patients with illicit injecting drug use and can be explained
by the sharing of syringes and other injection equipments.
All HIV seropositive patients were under treatment of
antiviral therapy and followed by the local department of
infections disease and none had symptoms of acquired
immune deficiency syndrome.
Most disappointing was the 47.7 % implant failure rate at
10 years, 39.5 % due to deep sepsis. We are not aware of any
other series that have reported the outcomes in a similar
patient population; hence our results could be compared.
Looking to non-hemophilic HIV-positive patients, a
higher rate of septic complications can yet not be
concluded from the literature [12–16]. However, THA in
hemophilic HIV seropositive patients is indeed associated
with a high septic revision rate, which in Hicks’s series
[12] was as high as 18.7 % in primary and 36.4 % in
revision THA’s. In one of these series [16] a subgroup of 5
HIV-positive illicit injecting drug users was included and 3
of them were complicated by deep sepsis after 1, 1.5 and
15 months. In our present series none of the patients sus-
taining deep sepsis was HIV seropositive and HIV there-
fore does not explain the high revision rate.
The risk to cause and spread infection with self-colo-
nized strains has shown to be multiplied by injection or
inhalation of drugs [8, 9]. Furthermore, the rate of peri-
prosthetic joint infection after documented Staphylococcus
aureus bacteremia is reported to range from 30 to 40 %
[17]. It is, therefore, not surprising that injecting drug users
more often sustain septic complications after THA’s. In the
present series, all patients affirmatively stated and their
respective healthcare professionals confirmed abstinence
from illicit injecting drug use at the time of the index
procedure. Nevertheless, five patients admitted occasional
recurrence of illicit injecting drug use after the index
procedure. Abstinence of less than 1 year before index
procedure was significantly associated with recurrence of
illicit injecting drug use and both with septic failure of the
prosthesis. However, if the patients with recurrence of
illicit drug abuse were excluded, the septic failure rate
would still reach 25 %. Although other risk factors for
septic failure, such as younger age [18], alcohol abuse [19]
and heavy smoking [20] were present in our group of
patients, this still does not explain the exceedingly high
complication rate.
From our data, we are unable to elucidate whether this
high septic failure rate was due to the altered general health
status of patients, who recently stopped injecting drug use
thus making them more susceptible to infection or whether
these patients are simply at higher risk of relapse, which
they may not admit. In our study, drug tests [21, 22] in
order to verify abstinence from illicit drug use were not
performed. Additional limitations of the present study are
its retrospective nature with difficulties of complete follow-
up, the small group of patients with heterogenic indications
for THA and different co-morbidities limiting statistical
analysis. Furthermore, one can debate whether the origin of
periprosthetic infection was hematogenous as opposed to
an exogenous.
Despite these limitations valuable conclusions can be
made: (1) THA’s in patients with declared abstinence after
a history of illicit injecting drug use results in an unac-
ceptable high septic failure rate. (2) Declared abstinence of
less than 1 year before THA is more often associated with
recurrence of illicit drug abuse and both increase the risk of
septic implant failure.
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Therefore, from this study we have changed our current
practice and have adopted the results as evidence when
negotiating appropriate treatment of osteoarthritis with
patients and their supporting health care professionals. We
are also requesting hair analysis for drugs, documenting
abstinence of at least 1 year before indicating THA.
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